CClinicalTrials.gg
Status unknownNCT05318378Updated Apr 8, 2022

Inverting Grayscale Improves Detection of Proximal Femur Fracture

An interventional study of BIXAM in Diagnoses Disease, sponsored by Centre de l'arthrose, Paris. Status unknown at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-08.

Sponsored by Centre de l'arthrose, Paris · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Proximal femur fractures (PFF) are a worldwide public health concern. A delay in the diagnosis and treatment worsens the prognosis. Inversion of grayscale is a tool available on most X-rays visualization software, and its use has been suggested to improve radiological diagnosis. The study aims to determine if using inverted grayscale radiography results in better diagnoses of PFF among medical students.

Material and Methods. The investigators evaluated the detection of PFF by fifth-year medical students on a series of 30 pelvis X-rays. The series was composed of 20 X-rays with PFF and 10 X-rays without fracture. A first reading session was set up where X-rays were presented separately in conventional and inverted grayscale. A second session one month later showed both grayscale visualizations together (BIcontrast X-rays Analysis Method - BIXAM). X-rays' order of appearance was randomized. The investigators performed the same evaluation on senior orthopedic surgeons as a control. Finally, sensitivity, specificity, and accuracy were assessed for each method (conventional, inverted, and BIXAM) with the McNemar test. Subgroup analyses were performed on the fracture localization (femoral neck, trochanteric).

02

Conditions studied

  • Diagnoses Disease

Browse trials for

03

In context

Femoral Fractures

293 studies on the registry are indexed under Femoral Fractures; 47 are open to participants now.

This study's planned enrollment of 20 is below the median of 64 across 182 interventional studies indexed under Femoral Fractures.

Browse Femoral Fractures studies →

Lead sponsor

Centre de l'arthrose, Paris is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • fifth-year medical students

Exclusion criteria

Exclusion Criteria:

  • other medical students
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    student

    Twenty fifth-year medical students were asked to participate in the study

    Diagnostic Test: BIXAM

  • Active comparator
    senior surgeon

    As controls, we asked 3 independent board-certified orthopedic surgeons to participate in the study following the same conditions as described previously.

    Diagnostic Test: BIXAM

Interventions

  • Diagnostic testBIXAM

    Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together

06

What researchers measure

Primary outcomes

  1. accuracy

    accuracy was compared between conventional and inverted grayscales or both images shown together (BIXAM series) with non-parametric McNemar test

    Time frame: one month

  2. Sensibility, specificity,

    Sensibility, specificity were compared between conventional and inverted grayscales or both images shown together (BIXAM series) with non-parametric McNemar test

    Time frame: one month

07

Study locations

1 of 1 sites recruiting
  • Aphp
    Paris, 75018, France
    • maillot cedric, msc · Contact · 0611789158
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05318378
Lead sponsor
Centre de l'arthrose, Paris
Responsible party
Sponsor
First posted
Apr 8, 2022
Start date
Jan 31, 2022
Primary completion
Mar 31, 2022
Completion
Apr 30, 2022 (estimated)
Last update
Apr 8, 2022

Study contacts

cedric maillot, msc
Contact
cedric.maillot@aphp.fr
0611789158
cedric maillot
study director · APHP

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion